Cannabidiol significantly reduces chronic pain for those with nerve damage

by University of Sydney

edited by Lisa Lock, reviewed by Andrew Zinin

Lisa Lock

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Lead Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add as preferred source

A new study by researchers at the University of Sydney has shown that taking cannabidiol (CBD) can significantly reduce chronic neuropathic pain in those suffering from it. The findings of the randomized placebo-controlled trial, published in eClinicalMedicine, demonstrated that taking CBD over a six-week period reduced pain by approximately 14%, compared to 6.5% from the placebo.

CBD is a substance derived from the cannabis plant. Unlike tetrahydrocannabinol or "THC" it does not cause a high. In Australia, CBD is a prescription-only medication that is currently used to treat conditions such as drug-resistant epilepsy.

Lead author Dr Rebecca Robertson, from the Brain and Mind Center, said the results of the study were beyond what she expected. "Chronic neuropathic pain is notoriously hard to treat, with traditional therapies ineffective in about 50% of cases. To see such strong results in the trial is significant and suggests there is real potential for CBD to be used to help manage chronic neuropathic pain."

While the researchers found that pain was reduced on average by 14%, some trial participants reported a greater than 30% reduction in nerve pain when taking CBD. In addition to the pain reduction reported by the trial participants, CBD was well tolerated at high doses with few serious side effects.

How researchers carried out the trial

The research team recruited 40 adults aged 18 or over who experienced chronic neuropathic pain as a result of a spinal cord injury—though the researchers stress that the findings are relevant to all people who experience chronic neuropathic pain, not only those experiencing it as a result of a spinal cord injury. About 8.5% of Australians are estimated to live with chronic neuropathic pain.

Participants received either CBD tablets or a placebo tablet that matched the CBD tablet in look, taste and smell. They took the tablets every day, with the dose in the CBD tablet increasing over time from 200mg per day at the beginning of the trial to 800mg per day at the end.

Throughout the trial, participants were asked to complete a questionnaire three times a day on alternate weekdays, scoring their pain levels using a Visual Analog Scale going from 0 (no pain) to 10 (worst pain imaginable). This scale is a widely used clinical tool for measuring subjective experiences like pain.

Considerations from the study

Alongside the trial medication of CBD or a placebo, participants were also taking a wide range of medications to manage not only their spinal cord injury but other conditions. As CBD may interact with commonly prescribed medications, it is possible that these interactions could have had an impact on the pain reduction reported.

In addition, as 78% of the patients taking a placebo correctly guessed which tablet they were receiving, there is a possibility that those taking the placebo had lower expectations of the pain reduction they were likely to experience.

Next steps

Professor Iain McGregor, the study's co-investigator, said that he hopes the trial will pave the way for further research into the use of CBD in managing pain. "Further work is needed to understand why CBD worked better for some people than others, and also to understand how CBD might interact with other medications that participants were taking.

"In the long term, we hope this work will lead us towards developing treatments to manage pain more effectively."

Publication details

Rebecca V. Robertson et al, High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial, eClinicalMedicine (2026). DOI: 10.1016/j.eclinm.2026.103986

Journal information: EClinicalMedicine

Key medical concepts

CannabidiolNeuropathic PainSpinal Cord InjuriesplaceboVisual Analog Scale

Clinical categories

NeurologyClinical pharmacologyCommon illnesses & Prevention Provided by University of Sydney Who's behind this story?

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Cannabidiol significantly reduces chronic pain for those with nerve damage (2026, May 29) retrieved 29 May 2026 from https://medicalxpress.com/news/2026-05-cannabidiol-significantly-chronic-pain-nerve.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.